STEVENSON, Md., March 07, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ohr securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s lead product, Squalamine, would not produce vision improvements and was commercially not viable.
According to the complaint, following a January 5, 2018 report that topline data from its MAKO study did not meet its primary efficacy endpoint, the value of Ohr shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Ohr securities purchased on or after June 24, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
OpenAI Restricts Astra AI Over Cyberattack Risks
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 



